Skip to main content

Table 2 Release criteria of allo-UC-MSC administration

From: Allogeneic administration of human umbilical cord-derived mesenchymal stem/stromal cells for bronchopulmonary dysplasia: preliminary outcomes in four Vietnamese infants

Transplantation Patient 1 Patient 2 Patient 3 Patient 4
1st 2nd 1st 2nd 1st 2nd 1st 2nd
Cell doses (× 106 cells/kg) 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0
Cell viability (%) 97 97 96 98 98 98 97 89
CD73 (%) 97.9 98.5 98.5 98.3 98.4 99.63 99.5 99.6
CD90 (%) 100 100 100 100 100 99.7 100 99.9
CD105 (%) 100 100 100 100 100 100 100 100
Negative markers* (%) 0.9 0.3 0.3 0.7 0.1 0.1 0.0 0.0
Microorganism and fungal tests Negative
Mycoplasma Negative
Endotoxin (EU/ml)  < 0.1  < 0.05  < 0.1  < 0.1 0.073  < 0.05  < 0.05  < 0.05
Karyotyping 46, XY, 16qh + 
CFU assay (CFU per 1000 cells) 519 ± 80
Adipogenesis Pass
Chondrogenesis Pass
Osteogenesis Pass
  1. * CD11b, CD19, CD34, CD45, and HLR-DR